A recent, large study from the MD Anderson Cancer Center did not find an association between HER2 status and clinical outcomes in 919 HR + /HER2- aBC patients treated with first-line ET plus CDK4/6 inhibitors15. This evidence concerns the gene CDK4 and aneurysmal bone cyst.